Stromal gene signatures in large-B-cell lymphomas

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Rituximab plus CHOP chemotherapy (R-CHOP) improved survival in diffuse large-B-cell lymphoma (DLBCL).
• The correlation between gene-expression signatures and survival in DLBCL patients post-treatment remains unclear.

Purpose of the Study:

• To investigate the relationship between gene-expression signatures and patient survival in DLBCL.
• To develop and validate a gene-expression-based survival predictor for DLBCL.

Main Methods:

• Gene expression profiling of pretreatment biopsy specimens from 181 CHOP-treated and 233 R-CHOP-treated DLBCL patients.
• Development of a multivariate gene-expression-based survival predictor model using a training group.
• Validation of the predictive model in a separate patient group.

Main Results:

• A multivariate model incorporating "germinal-center B-cell," "stromal-1," and "stromal-2" gene-expression signatures predicted survival in both CHOP and R-CHOP treatment groups.
• "Stromal-1" signature, associated with favorable prognosis, indicated extracellular-matrix deposition and histiocytic infiltration.
• "Stromal-2" signature, linked to unfavorable prognosis, reflected increased tumor blood-vessel density (angiogenesis).

Conclusions:

• Tumor microenvironment factors, including immune cell infiltration, fibrosis, and angiogenesis, significantly influence survival outcomes in DLBCL patients.
• Gene-expression signatures can serve as valuable biomarkers for predicting survival in DLBCL.
• Understanding these molecular signatures may guide future therapeutic strategies for DLBCL.